ZA200404546B - Prodrugs to D-prolines. - Google Patents
Prodrugs to D-prolines. Download PDFInfo
- Publication number
- ZA200404546B ZA200404546B ZA200404546A ZA200404546A ZA200404546B ZA 200404546 B ZA200404546 B ZA 200404546B ZA 200404546 A ZA200404546 A ZA 200404546A ZA 200404546 A ZA200404546 A ZA 200404546A ZA 200404546 B ZA200404546 B ZA 200404546B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- pyrrolidin
- pyrrolidine
- hexanoyl
- carboxylic acid
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title claims description 25
- 229940002612 prodrug Drugs 0.000 title claims description 25
- 150000008567 D-prolines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- -1 (R)-1-[6-[ (R)-2-carbamoylmethoxycarbonyl-pyrrolidin-1-yl]-6-oxo-hexanoyl]- pyrrolidine-2-carboxylic acid Chemical compound 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- YHRVOMRERVCOSF-HZPDHXFCSA-N (12r,21r)-14,19-dioxa-1,8-diaza-tricyclo[19.3.0.0 8,12]tetracos-16-ene-2,7,13,20-tetraone Chemical compound O=C1OCC=CCOC(=O)[C@H]2CCCN2C(=O)CCCCC(=O)N2CCC[C@@H]21 YHRVOMRERVCOSF-HZPDHXFCSA-N 0.000 claims description 5
- ZBXTVWGKMYQKKY-WOJBJXKFSA-N (12r,25r)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacos-18-ene-2,7,13,24-tetraone Chemical compound O=C1OCCCC=CCCCOC(=O)[C@H]2CCCN2C(=O)CCCCC(=O)N2CCC[C@@H]21 ZBXTVWGKMYQKKY-WOJBJXKFSA-N 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 5
- IJMOHMDWGCPEBK-QZTJIDSGSA-N (12r,23r)-14,21-dioxa-1,8-diaza-tricyclo[21.3.0.0 8,12]hexacos-17-ene-2,7,13,22-tetraone Chemical compound O=C1OCCC=CCCOC(=O)[C@H]2CCCN2C(=O)CCCCC(=O)N2CCC[C@@H]21 IJMOHMDWGCPEBK-QZTJIDSGSA-N 0.000 claims description 4
- BPGABBDVQULVIB-QZTJIDSGSA-N (12r,23r)-14,21-dioxa-1,8-diaza-tricyclo[21.3.0.0 8,12]hexacosane-2,7,13,22-tetraone Chemical compound O=C1OCCCCCCOC(=O)[C@H]2CCCN2C(=O)CCCCC(=O)N2CCC[C@@H]21 BPGABBDVQULVIB-QZTJIDSGSA-N 0.000 claims description 4
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- AXISFHMHMRUXGJ-ZIAGYGMSSA-N methyl (2r)-1-[6-[(2r)-2-methoxycarbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OC)CCC1 AXISFHMHMRUXGJ-ZIAGYGMSSA-N 0.000 claims description 4
- PSJDGERJSFOWBV-HZPDHXFCSA-N (12r,21r)-14,19-dioxa-1,8-diaza-tricyclo[19.3.0.0 8,12]tetracosane-2,7,13,20-tetraone Chemical compound O=C1OCCCCOC(=O)[C@H]2CCCN2C(=O)CCCCC(=O)N2CCC[C@@H]21 PSJDGERJSFOWBV-HZPDHXFCSA-N 0.000 claims description 3
- LWNWQUXDIOITSD-WOJBJXKFSA-N (12r,25r)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacosane-2,7,13,24-tetraone Chemical compound O=C1OCCCCCCCCOC(=O)[C@H]2CCCN2C(=O)CCCCC(=O)N2CCC[C@@H]21 LWNWQUXDIOITSD-WOJBJXKFSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- JQHWUXXTBBJQGT-QZTJIDSGSA-N [2-(dimethylamino)-2-oxoethyl] (2r)-1-[6-[(2r)-2-[2-(dimethylamino)-2-oxoethoxy]carbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CN(C)C(=O)COC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC(=O)N(C)C)CCC1 JQHWUXXTBBJQGT-QZTJIDSGSA-N 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 108090001069 Chymopapain Proteins 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 239000002904 solvent Substances 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 23
- 239000000243 solution Substances 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 239000000284 extract Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- HZLAWYIBLZNRFZ-VXGBXAGGSA-N cphpc Chemical compound OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(O)=O)CCC1 HZLAWYIBLZNRFZ-VXGBXAGGSA-N 0.000 description 14
- 229960003010 sodium sulfate Drugs 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940093499 ethyl acetate Drugs 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229960001407 sodium bicarbonate Drugs 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 235000009518 sodium iodide Nutrition 0.000 description 8
- 229920001429 chelating resin Polymers 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- YBGRBHANPYBXIY-FGZHOGPDSA-N pent-4-enyl (2r)-1-[6-oxo-6-[(2r)-2-pent-4-enoxycarbonylpyrrolidin-1-yl]hexanoyl]pyrrolidine-2-carboxylate Chemical compound C=CCCCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCCCC=C)CCC1 YBGRBHANPYBXIY-FGZHOGPDSA-N 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- SFQKDJFRYSGABT-NHCUHLMSSA-N ethyl (2r)-1-[6-oxo-6-[(2r)-2-phenylmethoxycarbonylpyrrolidin-1-yl]hexanoyl]pyrrolidine-2-carboxylate Chemical compound CCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC=2C=CC=CC=2)CCC1 SFQKDJFRYSGABT-NHCUHLMSSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- UVGSHBSTSDVCDB-ZIAGYGMSSA-N (2-amino-2-oxoethyl) (2r)-1-[6-[(2r)-2-(2-amino-2-oxoethoxy)carbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound NC(=O)COC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC(N)=O)CCC1 UVGSHBSTSDVCDB-ZIAGYGMSSA-N 0.000 description 2
- XRHUQJHOLVGXGQ-LIKPIUCQSA-N 1-(2,2-dimethylpropanoyloxy)ethyl (2r)-1-[6-[(2r)-2-[1-(2,2-dimethylpropanoyloxy)ethoxycarbonyl]pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CC(C)(C)C(=O)OC(C)OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OC(C)OC(=O)C(C)(C)C)CCC1 XRHUQJHOLVGXGQ-LIKPIUCQSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 2
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 description 2
- CPQZQZNYTZXXBB-UHFFFAOYSA-N 2-chloro-n,n-di(propan-2-yl)acetamide Chemical compound CC(C)N(C(C)C)C(=O)CCl CPQZQZNYTZXXBB-UHFFFAOYSA-N 0.000 description 2
- CQQUWTMMFMJEFE-UHFFFAOYSA-N 2-chloro-n,n-diethylacetamide Chemical compound CCN(CC)C(=O)CCl CQQUWTMMFMJEFE-UHFFFAOYSA-N 0.000 description 2
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 2
- ZPWIVSGEQGESFF-UHFFFAOYSA-N 2-chloro-n-cyclopropylacetamide Chemical compound ClCC(=O)NC1CC1 ZPWIVSGEQGESFF-UHFFFAOYSA-N 0.000 description 2
- AZOOMRDAGOXGNJ-UHFFFAOYSA-N 2-chloro-n-prop-2-enylacetamide Chemical compound ClCC(=O)NCC=C AZOOMRDAGOXGNJ-UHFFFAOYSA-N 0.000 description 2
- GYPNJSBBOATUPK-UHFFFAOYSA-N 2-chloro-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)CCl GYPNJSBBOATUPK-UHFFFAOYSA-N 0.000 description 2
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 2
- 102100036202 Serum amyloid P-component Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FZETVRVPFSOUAD-FGZHOGPDSA-N [2-(diethylamino)-2-oxoethyl] (2r)-1-[6-[(2r)-2-[2-(diethylamino)-2-oxoethoxy]carbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CCN(CC)C(=O)COC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC(=O)N(CC)CC)CCC1 FZETVRVPFSOUAD-FGZHOGPDSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CADMZSIBAIEPFR-WOJBJXKFSA-N but-3-enyl (2r)-1-[6-[(2r)-2-but-3-enoxycarbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound C=CCCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCCC=C)CCC1 CADMZSIBAIEPFR-WOJBJXKFSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- PMWFASNWZJXHIM-UHFFFAOYSA-N n-tert-butyl-2-chloro-n-methylacetamide Chemical compound CC(C)(C)N(C)C(=O)CCl PMWFASNWZJXHIM-UHFFFAOYSA-N 0.000 description 2
- NQVPSGXLCXZSTB-UHFFFAOYSA-N n-tert-butyl-2-chloroacetamide Chemical compound CC(C)(C)NC(=O)CCl NQVPSGXLCXZSTB-UHFFFAOYSA-N 0.000 description 2
- LQAVWYMTUMSFBE-UHFFFAOYSA-N pent-4-en-1-ol Chemical compound OCCCC=C LQAVWYMTUMSFBE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- RZESSDQDMPVBQK-UHFFFAOYSA-N (2-amino-2-oxoethyl) pyrrolidine-2-carboxylate Chemical compound NC(=O)COC(=O)C1CCCN1 RZESSDQDMPVBQK-UHFFFAOYSA-N 0.000 description 1
- PJEZRHWCORTKKF-ZIAGYGMSSA-N (2r)-1-[6-[(2r)-2-ethoxycarbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid Chemical compound CCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(O)=O)CCC1 PJEZRHWCORTKKF-ZIAGYGMSSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SATKWGUTVPCWFY-UHFFFAOYSA-N 1-bromoethyl 2,2-dimethylpropanoate Chemical compound CC(Br)OC(=O)C(C)(C)C SATKWGUTVPCWFY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 150000008626 4-imidazolidinones Chemical class 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010016202 Familial Amyloidosis Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000002794 Glucosephosphate Dehydrogenase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AZFOFVRIIMZFOP-WOJBJXKFSA-N [2-(cyclopropylamino)-2-oxoethyl] (2r)-1-[6-[(2r)-2-[2-(cyclopropylamino)-2-oxoethoxy]carbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound O=C([C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)OCC(=O)NC1CC1)OCC(=O)NC1CC1 AZFOFVRIIMZFOP-WOJBJXKFSA-N 0.000 description 1
- PKTCEKPWFLTPBC-WOJBJXKFSA-N [2-(tert-butylamino)-2-oxoethyl] (2r)-1-[6-[(2r)-2-[2-(tert-butylamino)-2-oxoethoxy]carbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CC(C)(C)NC(=O)COC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC(=O)NC(C)(C)C)CCC1 PKTCEKPWFLTPBC-WOJBJXKFSA-N 0.000 description 1
- TWGXMOPWAMHCOZ-CLJLJLNGSA-N [2-[di(propan-2-yl)amino]-2-oxoethyl] (2r)-1-[6-[(2r)-2-[2-[di(propan-2-yl)amino]-2-oxoethoxy]carbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CC(C)N(C(C)C)C(=O)COC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC(=O)N(C(C)C)C(C)C)CCC1 TWGXMOPWAMHCOZ-CLJLJLNGSA-N 0.000 description 1
- VSNMIMZXSCSYGE-LMHXZZLNSA-N [3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl] (2r)-1-[6-[(2r)-2-[3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]oxycarbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CNC(=O)C(C(C)(C)C)OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OC(C(=O)NC)C(C)(C)C)CCC1 VSNMIMZXSCSYGE-LMHXZZLNSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- UTXWKODCVFCPPV-WOJBJXKFSA-N butyl (2r)-1-[6-[(2r)-2-butoxycarbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CCCCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCCCC)CCC1 UTXWKODCVFCPPV-WOJBJXKFSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- NPICUOIVRRJDGX-HZPDHXFCSA-N ethyl (2r)-1-[6-[(2r)-2-ethoxycarbonylpyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylate Chemical compound CCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(=O)OCC)CCC1 NPICUOIVRRJDGX-HZPDHXFCSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000017105 hereditary amyloidosis Diseases 0.000 description 1
- YVVBWGQRYXCXMY-UHFFFAOYSA-N hexacos-17-ene-2,7,13,22-tetrone Chemical compound CC(CCCCC(CCCCCC(CCCC=CCCCC(CCCC)=O)=O)=O)=O YVVBWGQRYXCXMY-UHFFFAOYSA-N 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129793 | 2001-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200404546B true ZA200404546B (en) | 2006-02-22 |
Family
ID=8179542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200404546A ZA200404546B (en) | 2001-12-14 | 2004-06-08 | Prodrugs to D-prolines. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6903129B2 (no) |
| EP (2) | EP1743884A1 (no) |
| JP (1) | JP4192100B2 (no) |
| KR (1) | KR100678785B1 (no) |
| CN (1) | CN100368397C (no) |
| AR (1) | AR038010A1 (no) |
| AU (1) | AU2002361982B2 (no) |
| BR (1) | BR0214932A (no) |
| CA (1) | CA2470037C (no) |
| GT (1) | GT200200275A (no) |
| HK (1) | HK1076100A1 (no) |
| HR (1) | HRP20040494A2 (no) |
| HU (1) | HUP0402600A3 (no) |
| IL (2) | IL162158A0 (no) |
| MX (1) | MXPA04005693A (no) |
| MY (1) | MY129431A (no) |
| NO (1) | NO20042979L (no) |
| NZ (1) | NZ533188A (no) |
| PA (1) | PA8561201A1 (no) |
| PE (1) | PE20030764A1 (no) |
| PL (1) | PL370803A1 (no) |
| RU (1) | RU2305679C2 (no) |
| TW (1) | TWI225400B (no) |
| UY (1) | UY27584A1 (no) |
| WO (1) | WO2003051836A1 (no) |
| ZA (1) | ZA200404546B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| RU2530601C2 (ru) * | 2012-10-05 | 2014-10-10 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Ингибитор образования цинк-зависимых димеров бета-амилоида |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201407506D0 (en) * | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| SI0915088T1 (en) | 1997-10-31 | 2002-12-31 | F. Hoffmann-La Roche Ag | D-proline derivatives |
-
2002
- 2002-12-02 US US10/307,699 patent/US6903129B2/en not_active Expired - Lifetime
- 2002-12-06 HU HU0402600A patent/HUP0402600A3/hu unknown
- 2002-12-06 CN CNB028249348A patent/CN100368397C/zh not_active Expired - Fee Related
- 2002-12-06 WO PCT/EP2002/013827 patent/WO2003051836A1/en not_active Application Discontinuation
- 2002-12-06 RU RU2004121783/04A patent/RU2305679C2/ru not_active IP Right Cessation
- 2002-12-06 EP EP06020711A patent/EP1743884A1/en not_active Withdrawn
- 2002-12-06 BR BR0214932-0A patent/BR0214932A/pt not_active Application Discontinuation
- 2002-12-06 IL IL16215802A patent/IL162158A0/xx unknown
- 2002-12-06 PL PL02370803A patent/PL370803A1/xx not_active Application Discontinuation
- 2002-12-06 AU AU2002361982A patent/AU2002361982B2/en not_active Ceased
- 2002-12-06 CA CA2470037A patent/CA2470037C/en not_active Expired - Fee Related
- 2002-12-06 JP JP2003552723A patent/JP4192100B2/ja not_active Expired - Fee Related
- 2002-12-06 EP EP02796578A patent/EP1458680A1/en not_active Withdrawn
- 2002-12-06 NZ NZ533188A patent/NZ533188A/en not_active IP Right Cessation
- 2002-12-06 KR KR1020047009036A patent/KR100678785B1/ko not_active IP Right Cessation
- 2002-12-06 MX MXPA04005693A patent/MXPA04005693A/es active IP Right Grant
- 2002-12-10 PE PE2002001184A patent/PE20030764A1/es not_active Application Discontinuation
- 2002-12-11 PA PA20028561201A patent/PA8561201A1/es unknown
- 2002-12-11 TW TW091135829A patent/TWI225400B/zh not_active IP Right Cessation
- 2002-12-12 AR ARP020104818A patent/AR038010A1/es unknown
- 2002-12-13 MY MYPI20024679A patent/MY129431A/en unknown
- 2002-12-13 GT GT200200275A patent/GT200200275A/es unknown
- 2002-12-13 UY UY27584A patent/UY27584A1/es not_active Application Discontinuation
-
2004
- 2004-05-24 IL IL162158A patent/IL162158A/en not_active IP Right Cessation
- 2004-06-01 HR HR20040494A patent/HRP20040494A2/hr not_active Application Discontinuation
- 2004-06-08 ZA ZA200404546A patent/ZA200404546B/en unknown
- 2004-07-13 NO NO20042979A patent/NO20042979L/no not_active Application Discontinuation
-
2005
- 2005-09-16 HK HK05108123A patent/HK1076100A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002212745B2 (en) | Cyanopyrrolidine derivatives | |
| EP1940817B1 (en) | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | |
| FI63571C (fi) | Foerfarande foer framstaellning av analgetiskt verkande racemiska eller diastereomera och optiskt aktiva 2-tetrahydrofurfuryl-(1r/s 5r/s 9r/s)-2'-hydroxi-5,9-dimetyl-6,7-bensomorfaner och deras syraadditionssalter | |
| US5760235A (en) | Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof | |
| JPS6126781B2 (no) | ||
| JP2000505810A (ja) | アポｂ−分泌／ｍｔｐ阻害性アミド | |
| SK48398A3 (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| EA013057B1 (ru) | N-ацильные производные аминокислот, способ их получения, фармацевтическая композиция и применение в качестве противоаллергических, противовоспалительных и гиполипидемических средств | |
| HRP980572A2 (en) | D-proline derivatives | |
| JP2001501955A (ja) | 新規のピペリジン―ケトカルボン酸誘導体、その製造および使用 | |
| CA2470037C (en) | Prodrugs to d-prolines | |
| AU694495B2 (en) | Antagonists of endothelin receptors | |
| JPS6383053A (ja) | 環状脂肪族アルコールのアミノ酸エステル類、その製法と医薬組成物 | |
| RU2272027C2 (ru) | Производные 3-гидроксипиперидина и фармацевтическая композиция на их основе | |
| MXPA06003895A (es) | Pentan-2-oles sustituidos con 1-(quinolin-amino) y 1-(isoquinolin-amino), un procedimiento para prepararlos, y su uso como antiinflamatorios. | |
| JPS6097963A (ja) | ビス−ジオキソピペラジン誘導体，その製造方法及びそれからなる抗腫瘍剤 | |
| KR20130026081A (ko) | 뮤라야폴린 에이 유도체를 유효성분으로 함유하는 혈관 질환의 치료 또는 예방용 조성물 | |
| CN117736201A (zh) | 靶向组蛋白去乙酰化酶8蛋白水解嵌合体、制备方法及其应用 | |
| KR20010012299A (ko) | 신규 헤테로고리 화합물 | |
| GB2135300A (en) | 4-Aminobutyric acid derivatives and processes for the preparation thereof | |
| GB2185479A (en) | X,b-dilydroxy benzene-ethanamides as natural products | |
| HU211088B (en) | Process for producing peptide derivates inhibiting coagulation of blood and pharmaceutical compositions containing them | |
| BG60367B2 (bg) | Аминокиселинни производни |